Satsuma Pharmaceuticals Current Cash

Satsuma Pharmaceuticals (STSA) currently reports a current cash of $20M as of March 2023. That compares with $21M in the prior-year period — down 8.6% year over year. Use the charts on this page to explore Satsuma Pharmaceuticals's current cash history and peer comparisons.

Satsuma Pharmaceuticals's current cash decreased from $21M to $20M — a 8.6% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Satsuma Pharmaceuticals reported $20M in current cash as of March 2023. That compares with $21M in the prior-year period — down 8.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Satsuma Pharmaceuticals, and consider following STSA for alerts when major investors trade the stock.

Satsuma Pharmaceuticals is classified in the Healthcare sector. On current cash, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing STSA with unrelated industries.